Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Post by Speyeder999on Jan 02, 2022 2:56pm
286 Views
Post# 34277514

Hans Frykman

Hans Frykman

Hello and good year to all.

Decided to get the ball rolling in 2022 with an observation I made recently looking at Promis's revamped web site and noticed that Hans Frykman is no longer on their scientific advisory board. 

I will admit that I'm a little disappointed even though there seemed little hope in anything coming out of the Immusafe effort, his absence on the SAB seems to put the nail in the coffin. I always hoped that Promis would piggyback off the COViD experience   to legitimize their science in the ALS and Alzheimer field to least propel their share price to the 0.40-0.50 range before consolidation.....
who knows, this might still be in the works, but you have to wonder why Hans is no longer there.
Any thoughts?
 

<< Previous
Bullboard Posts
Next >>